Fate Therapeutics Grants New Employee Inducement Awards: Impact on Company Shares Assessed
San Diego-based biopharmaceutical company, Fate Therapeutics, has recently announced the granting of restricted stock units (RSUs) to two newly-hired non-executive employees.The RSUs, totaling 32,600 shares, have been approved by the Compensation Committee of the Company’s Board of Directors and granted under the Amended and Restated Inducement Equity Plan.This move has been deemed as an inducement to attract these new employees, in accordance with Nasdaq Listing Rule 5635(c)(4).
Under this plan, the RSUs will vest over a four-year period.Each RSU award will vest in annual increments on the anniversary of the grant date, with 25% of the shares underlying each RSU vesting on each anniversary.However, this vesting is subject to the condition that the employees remain continuously employed by the Company until each vesting date.
The impact of these new employee inducement awards on Fate Therapeutics’ shares can be analyzed by considering the total number of outstanding shares and the current share price.As of now, the company has 98,568,012 million shares outstanding, with each share valued at $6.76.
With the introduction of the 32,600 RSUs, representing newly granted shares, the percentage of ownership held by existing shareholders will slightly dilute.This dilution effect occurs because the new shares will increase the overall share count, and thus, reduce the proportional ownership of existing shareholders.
However, the overall impact of these inducement awards on the company shares is likely to be minimal.The number of shares granted represents a relatively small fraction (approximately 0.03%) of the total outstanding shares.Additionally, the four-year vesting period and the requirement for continuous employment ensure that the awarded shares will be distributed gradually over time, rather than hitting the market all at once.
It is worth noting that inducement equity plans are commonly utilized by companies to attract and retain top talent, especially when recruiting non-executive employees.By offering RSUs, Fate Therapeutics aims to incentivize and align the interests of their newly-hired staff with those of the existing shareholders.
In conclusion, while the recent inducement awards will result in some dilution of existing shareholders’ ownership, the impact on Fate Therapeutics’ shares is expected to be minimal given the relatively small number of shares granted and the gradual vesting process.These inducement awards reflect the company’s commitment to attracting and retaining talented individuals as it pursues its mission of developing innovative stem cell therapies for cancer and autoimmune disorders.
Comments